GIST & neuroendocrine

Part 1: Gastrointestinal Stromal Tumors (GIST)

1. Definition & Origin

• Cell of Origin: Interstitial Cells of Cajal (ICCs) — the “pacemaker cells” of the GI tract responsible for peristalsis (gut motility), or their stem cell precursors.
• Classification: The most common mesenchymal neoplasm of the GI tract (distinct from carcinomas, which are epithelial). Classified as a Soft Tissue Sarcoma.

2. Molecular Pathogenesis (The Defining Feature)

>85% of GISTs are driven by gain-of-function mutations in receptor tyrosine kinases.

3. Epidemiology & Site

• Incidence: ~4,000–6,000 cases/year (USA).
• Median Age: 60–65 years.
• Primary Sites: Stomach (60%), Small Intestine (30–35%), Rectum (5%), Esophagus (<1%), Mesentery/Omentum (rare, “Extra-gastrointestinal GIST”).

4. Clinical Presentation

• Asymptomatic: Incidental finding on imaging/endoscopy (increasingly common).
• Symptomatic: GI bleeding (hematemesis, melena, anemia — most common), abdominal pain, palpable mass, early satiety, obstruction, perforation (rare).
• Paraneoplastic: Hypoglycemia (rare, due to IGF-2 secretion).

5. Diagnosis & Pathology

• Immunohistochemistry (IHC):
  • CD117 (c-KIT): Positive in ~95% (Gold standard).
  • DOG1: Positive in ~98% (More sensitive/specific; positive in KIT-negative GISTs).
  • CD34: ~70% positive.
  • Desmin / S100 / SMA: Usually Negative (helps rule out leiomyoma, schwannoma).
• Molecular Testing (Mandatory): KIT/PDGFRA genotyping required before starting systemic therapy to guide drug selection.

6. Risk Stratification (Prognosis)

Used for localized disease post-resection to determine need for adjuvant therapy.

• Modified NIH Criteria (Fletcher/Miettinen): Based on Tumor Size and Mitotic Count (per 5 mm²).
• AFIP / Miettinen Criteria: Adds Anatomic Site (Gastric vs. Non-gastric have better prognosis for same size/mitoses).
• Tumor Rupture: Upstages to High Risk / Stage IV (peritoneal contamination).

7. Staging (AJCC 8th Ed / TNM)

• Based on Size, Mitotic Rate, Site, and Metastasis.
• No formal “Stage Grouping” for survival curves in AJCC 8th; uses Risk Categories.

8. Treatment Algorithm

A. Localized Disease (Resectable)

• Surgery: En bloc R0 resection (negative margins). Lymphadenectomy NOT required (GISTs rarely metastasize to lymph nodes; hematogenous spread to liver/peritoneum).
• Laparoscopic vs. Open: Laparoscopic acceptable for tumors <5 cm (avoid rupture).
• Adjuvant Imatinib (3 years standard):
  • High Risk: 3 years standard; consider 5 years (SSGXVIII/AIO trial showed 5yr OS benefit).
  • Intermediate Risk: Individualized (often 1–3 years).
  • Low/Very Low Risk: Observation.
• Neoadjuvant Imatinib: For borderline resectable, large tumors, or to preserve organ function (sphincter). Typical duration: 6–12 months pre-op.

B. Metastatic / Unresectable Disease

• First Line: Imatinib 400 mg/day (Standard). 800 mg/day for KIT Exon 9 mutation.
• Response Assessment: CT scan at 2–3 months. CHOI Criteria or PERCIST (PET-CT) preferred over RECIST (GISTs often necrose/cystically degenerate without shrinking).
• Progression on Imatinib:
  1. Sunitinib (2nd Line): 50 mg 4/2 schedule. Benefit in KIT Exon 9, WT.
  2. Regorafenib (3rd Line): 160 mg 3 weeks on/1 week off.
  3. Ripretinib (4th Line+): Broad KIT switch-control inhibitor. Standard 4th line.
  4. Avapritinib: Specific for PDGFRA Exon 18 (D842V) — 1st line standard for this mutation. Not for standard KIT-mutant GIST (toxicity/cognitive effects).
  5. NTRK Inhibitors (Larotrectinib/Entrectinib): For NTRK fusion+ GIST (rare).
• Surgery in Metastatic Setting: “Debulking” or metastasectomy considered only for oligoprogression on TKI (stable disease elsewhere) or symptomatic relief. Multidisciplinary decision.

9. Follow-up

• CT Abdomen/Pelvis: Every 3–6 months for 5 years, then annually (liver/peritoneum most common recurrence sites).
• PET-CT: For equivocal CT findings or early response assessment.

Part 2: Neuroendocrine Tumors (NETs) — Gastroenteropancreatic (GEP-NETs)

1. Definition & Origin

• Cell of Origin: Neuroendocrine cells (diffuse neuroendocrine system) — amine precursor uptake and decarboxylation (APUD) cells. Share features of neurons (synaptophysin, chromogranin) and endocrine cells (hormone secretion).
• Classification: Epithelial neoplasms (Carcinomas).
• Terminology Shift: “Carcinoid” is outdated but still used for well-differentiated NETs of GI tract/lungs. Preferred: Well-differentiated NET (Grade 1/2) vs. Poorly differentiated Neuroendocrine Carcinoma (NEC, Grade 3).

2. Classification & Grading (WHO 2019 / WHO 2022 Digestive Systems)

Critical Distinction: Differentiation + Grade (Ki-67 / Mitotic Count)

3. Functional vs. Non-Functional

• Functional (Syndromic): Secrete bioactive peptides causing clinical syndromes.
  • Carcinoid Syndrome: Serotonin → Flushing, Diarrhea, Valvular Heart Disease (Right sided), Bronchospasm. (Midgut NETs + Liver Mets).
  • Insulinoma: Hypoglycemia (Pancreas).
  • Gastrinoma (Zollinger-Ellison): Ulcers, Diarrhea (Duodenum/Pancreas).
  • Glucagonoma, VIPoma, Somatostatinoma: Rare.
• Non-Functional: Majority (esp. Pancreatic NETs). Present via mass effect or metastatic burden.

4. Primary Sites & Epidemiology

• Incidence: Rising sharply (better detection). ~170,000 patients living in US.
• Common Sites: Small Intestine (Ileum – “Midgut”), Lung, Rectum, Pancreas, Appendix, Stomach, Colon.
• Hereditary Syndromes: MEN1 (Pancreatic NETs, Parathyroid, Pituitary), VHL (Pancreatic NETs), NF1 (Duodenal Somatostatinoma), TSC (Pancreatic NETs).

5. Diagnosis & Workup

1. Biochemistry:
   • Chromogranin A (CgA): General marker (↑ in renal failure, PPI use — false +).
   • Specific Hormones: Insulin, Gastrin, Glucagon, VIP, PP, Serotonin (5-HIAA urine).
   • 24-hr Urine 5-HIAA: Gold standard for Carcinoid Syndrome (dietary restrictions needed).
2. Cross-sectional Imaging: Multiphasic CT (Arterial phase critical for hypervascular NETs) or MRI Liver (gold standard for liver mets).
3. Functional Imaging (Somatostatin Receptor Imaging):
   • Ga-68 DOTATATE PET/CT: Gold Standard. High sensitivity for SSTR2+ tumors (Well-diff NETs).
   • FDG PET/CT: Essential for High Grade (G3/NEC) or dedifferentiated tumors (Warburg effect). Discordance (High FDG / Low DOTATATE) = Poor prognosis.
4. Endoscopy: EUS (Pancreas/Rectum/Stomach), Colonoscopy (Ileal/Rectal), Capsule Endoscopy (Occult Small Bowel).
5. Pathology: Ki-67 index is mandatory. IHC: Synaptophysin, Chromogranin A, CD56, SSTR2a. Ki-67 must be assessed in highest proliferative area (hotspot).

6. Staging (AJCC 8th Ed / ENETS TNM)

• Site-specific staging systems (e.g., Pancreas, Stomach, Small Intestine, Appendix differ).
• General: T (Size/Invasion), N (Nodes), M (Mets).
• Stage IV: Distant mets (Liver #1, Bone, Lung, Peritoneum).

7. Treatment Algorithm (Multidisciplinary Tumor Board Mandatory)

A. Localized Disease (Stage I–III)

• Surgery = Curative Intent.
  • Small Bowel (Midgut): Resection + Mesenteric Lymphadenectomy (nodes almost always involved). Avoid “blind” resection; map mesentery.
  • Pancreas: Enucleation (small, non-functional, away from duct) vs. Formal Resection (Whipple, Distal Pancreatectomy). Lymphadenectomy standard.
  • Stomach/Rectum: Endoscopic resection (EMR/ESD) for small (<1cm), G1, no deep invasion, no nodes (Rectal NETs <1cm G1: endoscopic ok). Else formal surgery + nodes.
  • Appendix: <1cm, G1, margins neg, no nodes → Appendectomy. >2cm or high risk features → Right Hemicolectomy. 1–2cm: Controversial (consider nodes, LVI, margin).
• Adjuvant Therapy: No standard adjuvant chemo/TKI. Observation standard. Exception: Pancreatic NET G2/G3 with high risk features (R1, Node+), clinical trial or consider capecitabine/temozolomide (CAPTEM) based on extrapolated data.

B. Metastatic Disease (Stage IV) — “Chronic Management”

C. Special Scenarios

• Insulinoma: Surgery curative. Medical: Diazoxide, Everolimus, SSA (caution: can worsen hypoglycemia).
• Gastrinoma: High-dose PPI + Surgery (curative if localized). MEN1: Controversial surgery timing (often wait for >2cm primary).
• Carcinoid Heart Disease: Echocardiography screening (5-HIAA >300). Valve replacement often needed. SSA/PrRT may stabilize.
• Bone Mets: Bisphosphonates / Denosumab + PRRT / EBRT.

Part 3: Head-to-Head Comparison Summary

Key Clinical Pearls for the Practitioner

1. Don’t confuse “Spindle Cell” morphology:
   • GIST = CD117+/DOG1+ / Synaptophysin-.
   • NET = Synaptophysin+/Chromogranin+ / CD117-.
   • Rare overlap: Paraganglioma (S100+ sustentacular cells), but distinct clinical context.
2. Biopsy before Treatment: Never start Imatinib or SSA/PRRT without tissue diagnosis (except rare unresectable hepatic mets with classic imaging + biochemical profile).
3. Ki-67 is King in NETs: A “NET G3” (Well-diff, Ki-67 25%) behaves differently and gets different drugs than an “NEC G3” (Poorly diff, Ki-67 80%). Always verify differentiation status.
4. GIST Mutation Testing is Actionable:
   • PDGFRA D842V → Avapritinib (1st line). Do not give Imatinib.
   • KIT Exon 9 → Imatinib 800mg.
   • SDH-deficient / WT → Imatinib less effective; consider clinical trials / Sunitinib earlier.
5. PRRT Eligibility: Requires SSTR-positivity on Ga-68 DOTATATE PET (Krenning Score 3/4) and adequate renal function/hematologic reserve. Not for NEC (usually SSTR negative).
6. Surveillance Differs:
   • GIST: CT Abdomen/Pelvis (Liver/Peritoneum focus).
   • NETs: Multiphasic CT or MRI Liver + Ga-68 DOTATATE PET (Whole body) + Chromogranin A / 5-HIAA.
7. Carcinoid Crisis: Risk during surgery/anesthesia/embolization for functional NETs. Prophylaxis: Octreotide IV bolus + infusion peri-procedurally.

Disclaimer: This summary is for educational purposes. Oncology guidelines (NCCN, ESMO, ENETS, NANETS) update rapidly. Always refer to current guidelines and discuss cases in a multidisciplinary tumor board.